Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TempraMed Technologies Ltd. ( (TSE:VIVI) ) has provided an announcement.
TempraMed Technologies Ltd. has appointed Professor Dr. Lutz Heinemann, a leading diabetes researcher, to its Scientific Advisory Board. This strategic move aims to enhance TempraMed’s scientific leadership as it expands its portfolio of thermal-stability technologies for temperature-sensitive medications. Prof. Heinemann’s expertise in insulin pharmacology and diabetes technology is expected to strengthen TempraMed’s global partnerships, market access, and clinical validation efforts, ultimately improving medication safety and reliability for patients worldwide.
More about TempraMed Technologies Ltd.
TempraMed Technologies Ltd. is a global leader in innovative, temperature-controlled medication storage solutions. The company develops patented, FDA-registered thermal insulation devices that operate without batteries or external power, ensuring the effectiveness of life-saving medications. With products like VIVI Cap and VIVI Epi, TempraMed supports patients and healthcare providers in managing temperature-sensitive medications globally.
Average Trading Volume: 15,033
For an in-depth examination of VIVI stock, go to TipRanks’ Overview page.